BPC-157 Injection Dosage Chart: Study Doses by Route
Dosage chart of BPC-157 injection amounts used in published animal studies organized by route, species and outcome. Research reference only.
The dosage prescribed for BPC-157 injections mentioned in previous studies tends to be similar. Almost all experiments on rodents followed the same weight-based formulation: 10 micrograms per kilogram per day performed via intraperitoneal injection. This number can be seen in tendon, muscle, nerve, and arthritis experiments over the course of two decades. We gathered information concerning the dosage from six important works into one table below. There is no evidence available regarding human dosage. The FDA has not authorized BPC-157 for use in medicine. All figures in this article indicate what scientists gave to mammal animals in laboratory experiments.
BPC-157 Dosage in Published Studies
Understanding mcg/kg Dosing in Animal Models
In the veterinary pharmacology, dosages are presented in the unit of micrograms per kilogram (mcg/kg) of body weight. For example, a rat with a body mass of 250grams receiving 10 mcg/kg of the drug gets 2.5 mcg in total. Another rat with the body mass of 300 grams receives 3.0 mcg. So the weight-based measure helps researchers to standardize the dosage for different sizes of subjects belonging to one species. However, this measure is not directly applicable to species cross-species. Rats metabolize the drug much faster than dogs, while dogs metabolize it faster than humans. The ratio of mcg/kg is an experimental convention and cannot be used as a medical prescription.
Most BPC-157 studies tested a single dose level rather than a full dose-response curve. The Seiwerth et al. review (2018) noted that 10 mcg/kg was the most frequently reported dose across the literature. A smaller number of studies tested 10 ng/kg (a thousand-fold lower) and still reported measurable effects. This unusually wide effective range has not been explained mechanistically.
Why There Is No Human Dosage
BPC-157 has not been involved in a regulated clinical testing on humans with published pharmacokinetic data. Without knowledge of absorption, distribution, metabolism and excretion (ADME) in humans, there is no possibility of calculating the correct human dose. Allometric scaling using rats does not apply to peptides under normal conditions. There are too many differences in gastric enzymes and plasma half-life, clearance from the kidney and distribution in different types of tissue between mammals. So we do not provide information about the dosages for humans here.
Dosage Chart by Route and Study
The table below shows BPC-157 injection dosage data from six published studies. Each row lists the study author, animal species, administration route, dose, duration and primary outcome. All studies used rats.
| Study Author | Species | Route | Dose (mcg/kg) | Duration | Outcome | PMID |
|---|---|---|---|---|---|---|
| Seiwerth et al. 2018 (review) | Rat (multiple) | IP, oral, local | 10 (typical) | Varies | Consistent tissue-protective effects across models | 29998800 |
| Novinscak et al. 2008 | Rat | IP | 10 | 14 days | Accelerated muscle crush recovery, reduced edema | 18668315 |
| Chang et al. 2011 | Rat | Local | 10 and higher | 7-28 days | Promoted tendon fibroblast outgrowth and cell survival | 21030672 |
| Cerovecki et al. 2010 | Rat | IP | 10 | 14 days | Enhanced tendon-to-bone integration in detachment model | 20225319 |
| Gjurasin et al. 2010 | Rat | IP | 10 | 14 days | Faster axonal regeneration in transected sciatic nerve model | 19903499 |
| Sikiric et al. 1997 | Rat | IP | 10 | 28 days | Reduced paw swelling in adjuvant arthritis model | 9403784 |
Dose-Response Observations in Animal Data
Low-Dose vs High-Dose Findings
The chart above indicates an interesting trend: almost every study published used 10 mcg per kg. Only a few studies experimented with other dosages. Chang et al. (2011) tested on 10 mcg per kg and some higher dosages locally, but there is no established ceiling dose in the literature. The Sikiric review claims that some initial studies witnessed results when dosed at the level of 10 ng/kg. This marks a difference of a factor of 1000 relative to the conventional dose of 10 mcg/kg. It is still unclear whether using such low doses yields clinically meaningful effects or simply statistically significant results in carefully made rodents experiments.
The lack of systematic dose-escalation investigations is a disadvantage in the literature. We cannot determine with certainty whether a higher dose necessarily means higher effectiveness, less effectiveness, or even negative effects. The very few research works that conducted studies at different levels of doses did not report the complete results of dose-response curves with confidence intervals.
Duration of Administration
Most protocols administered BPC-157 daily for 14 days. Sikiric et al. (1997) extended their arthritis protocol to 28 days. Some acute studies measured effects after a single injection or 24-hour window. The pattern is consistent: daily dosing for 2 to 4 weeks. No study established a minimum effective duration or tested intermittent dosing schedules. Long-term safety data comes from a 24-month toxicology study in rats that reported no adverse findings, but chronic efficacy protocols beyond 4 weeks are rare.
Reconstitution Math for Common Vial Sizes
The following tables illustrate the concentrations resulting from the application of various water volumes to both 5mg and 10mg BPC-157 vials. These calculations are conducted using the arithmetic calculation method. The concentration can be defined as the ratio of peptide weight to the weight of the water used. The column that indicates per-0.1ml means the amount of the peptide in every line of the U-100 insulin syringe.
5mg Vial Concentration Table
| Water Added (ml) | Concentration (mg/ml) | mcg per 0.1ml | mcg per ml |
|---|---|---|---|
| 1.0 | 5.00 | 500 | 5000 |
| 1.5 | 3.33 | 333 | 3333 |
| 2.0 | 2.50 | 250 | 2500 |
| 2.5 | 2.00 | 200 | 2000 |
10mg Vial Concentration Table
| Water Added (ml) | Concentration (mg/ml) | mcg per 0.1ml | mcg per ml |
|---|---|---|---|
| 1.0 | 10.00 | 1000 | 10000 |
| 2.0 | 5.00 | 500 | 5000 |
| 2.5 | 4.00 | 400 | 4000 |
| 3.0 | 3.33 | 333 | 3333 |
| 5.0 | 2.00 | 200 | 2000 |
Why Animal Doses Cannot Be Converted to Human Doses
Body Surface Area Scaling Limitations
Pharmacologists often use body surface area scaling for the purpose of estimating human equivalent doses from animal data. The FDA’s guidance document for the first-in-human trials includes conversion factors by giving a multiplying factor of 0.162 to the dose in rats so as to derive the human equivalent dose in mg/kg. However, the conversion was based on small molecule drugs since it assumed that pharmacokinetics among species are the same. Peptides go against this assumption since they are broken down by species-specific enzymes. They bind to the plasma proteins that are specific to the different species. Their renal clearance also varies in rats and human beings. This site does not apply BSA scaling when it comes to BPC-157 due to the satisfaction of the conditions for validity not being met.
Route-Dependent Bioavailability Differences
In the published research, the most frequently used method is the intraperitoneal injection. This method is not used in human medicine. The interperitoneal injection involves administration of the active substance into the peritoneal cavity with later absorption into circulation through mesenteric vessels and the portal system. By comparison, the subcutaneous and intramuscular injections bypass the portal system entirely, hence having a distinct pharmacokinetic profile. If the dose has a therapeutic effect in rats via the intraperitoneal injection route, it does not mean that the subcutaneously or intramuscularly injected dose will be effective in humans, as the rate of absorption, maximum concentration, and AUC will differ. For concentration cut-offs, refer to our BPC-157 reconstitution calculator.
FAQ
What is the most common BPC-157 injection dose in animal studies?
The dose most often mentioned in clinical references appears to be 10 mcg/kg body weight administered by the intraperitoneal route and given once per day. The same dose has been studied in muscle and tendon, nerve and arthritis animal modeling efforts by many research centers. This indeed is a rat dose so not applicable to other species.
How long do BPC-157 injection protocols last in studies?
The majority of published protocols last 14 days with daily injections, some extending them for up to 28 days. Only very few studies concern protocols shorter than 7 days or longer than 4 weeks. The best protocol length in terms of a specific injury model is not known yet. For complete information on result submission timelines, visit our BPC-157 injection results page.
Can I calculate a human dose from the animal data?
We do not suggest this. BSA scaling, the conventional interspecies conversion technique, was created for small molecules and yields inaccurate results for peptides. BPC-157 has no human pharmacokinetics information available. Without any information on how humans absorb, distribute, metabolize, and excrete this product, any dosing calculations are pure guesswork. Consult with a knowledgeable healthcare provider before taking peptides.
Is 5mg or 10mg the right vial size?
Vial size determines how many draws you can take at a given concentration. A 10mg vial contains twice the peptide of a 5mg vial at a lower cost per milligram from most vendors. The choice depends on the total amount needed for a research protocol. See our 5mg vs 10mg comparison for a full breakdown of price, concentration and volume per draw. For injection technique details, see our injection guide.
BPC-157 is not approved for human medical use. The dosing information on this website refers only to animal studies. This information is not medical advice. Consult a physician on any interest in peptide products. BPC-157 is sold for research only.
Compare the current picks
Prices, sizes and ratings side by side, updated when the merchant pages change.
See top picks